Abstract: An air filtration assembly includes a mask that may be worn on a user's face. A pair of goggles is coupled to the mask. The pair of goggles covers the user's eyes when the user wears the mask. A sponge is coupled to the mask. A plurality of air intakes is coupled to the mask. The plurality of air intakes allows air to enter through the mask and the sponge when the user inhales. A plurality of fluid reservoirs is coupled to the mask. The plurality of fluid reservoirs each contains a fluid. The plurality of fluid reservoirs is compressed by the user when the user wears the mask. The fluid is dispersed into the sponge. The sponge filters particles from the air when the user inhales.

Abstract: Invented are pharmaceutical compositions containing paroxetine methanesulfonate.

Abstract: Invented is paroxetine hydrochloride anhydrate in Form B and paroxetine hydrochloride anhydrate in Form D. Also invented are pharmacetucal formulations comprising these compounds and methods of using these compounds in therapy.

Abstract: Paroxetine is adsorbed on a carrier to form a free-flowing powder useful for capsule filling or for tablet formulation; and used in therapy to treat depression.

Abstract: Invented are pharmaceutical compositions containing paroxetine methanesulfonate.

Abstract: Invented is paroxetine hydrochloride anhydrate in Form B and paroxetine hydrochloride anhydrate in Form D. Also invented are pharmaceutical formulations comprising these compounds and methods of using these compounds in therapy.

Abstract: Paroxetine is adsorbed on a carrier to form a free-flowing powder useful for capsule filling or for tablet formation; and used in therapy to treat depression.

Abstract: Paroxetine hydrochloride is obtained in an easily soluble form suitable for preparing stable aqueous solutions, suitable for parenteral use, by freeze-drying solutions prepared by dissolving paroxetine free base in aqueous hydrochloric acid, or of paroxetine hydrochloride hemihydrate or other hydrate/solvate/amorphous forms of paroxetine hydrochloride.

Abstract: Paroxetine hydrochloride is obtained in a free-flowing and easily soluble form (suitable for preparing solid formulations or aqueous solutions, suitable for parenteral use) by spry-drying solutions of paroxetine hydrochloride hemihydrate or other anhydrate/hydrate/solvate/amorphous forms.

Abstract: Paroxetine hydrochloride is obtained in a free-flowing and easily soluble form (suitable for preparing solid formulations or aqueous solutions, suitable for parenteral use) by spray-drying solutions of paroxetine hydrochloride hemihydrate or other anhydrate/hydrate/solvate/amorphous forms.

Abstract: Invented are pharmaceutical compositions containing paroxetine methanesulfonate.

Abstract: A process for preparing granisetron by cyclising a compound of structure (2).

Abstract: Compounds of structure (2) are prepared by reaction of an arecoline analogue of structure(4) with an organometallic compound containing an X-substituted phenyl group, such as a compound of structure (3). Suitably the compound of structure (3) is a Grignard reagent, where M is magnesium and Y is a halogen atom, or M may be a Group II metal and Y is a halogen atom or a second X-substituted phenyl group. When structure (3) is a Grignard reagent, the reaction is carried out either in a suitable non-ether solvent, typically a hydrocarbon or a non-reactive chlorinated hydrocarbon, or in a mixture of such a solvent with diethyl ether. Compounds of structure (2) are important intermediates in the preparation of inter alia paroxetine.

Abstract: Invented are methods of treatment using novel forms of paroxetine hydrochloride anhydrate.

Abstract: "Paroxetine hydrochloride (I) anhydrate free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated.

Abstract: Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.

Abstract: "Paroxetine hydrochloride (I) anhydrate ##STR1## free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated.

Abstract: "Paroxetine hydrochloride (I) anhydrate ##STR1## free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated.

Abstract: The present invention relates to paroxetine hydrochloride anhydrate substantially free of bound propan-2-ol, several forms of the above, processes for preparing the above, new intermediates useful in preparing the above and methods of treating and/or preventing certain diseases by administering the compounds of the invention to a patient in need thereof.

Abstract: A process for preparing a compound of structure (I) or a hydrate or solvate thereof in which R.sup.1 is C.sub.1-6 alkyl, optionally substituted phenyl or optionally substituted phenylC.sub.1-6 alkyl, which comprises reacting an azide of the structure (II): M.sup..sym. N.sub.3.sup..crclbar. with a cyanoformate of the structure (III): NC.CO.sub.2 R.sup.1 in which M is an alkali metal atom, and R.sup.1 is as described for structure (I), to form an intermediate salt of structure (IV), in which R.sup.1 is as described for structure (I) and M is as described for structure (II) followed by conversion of the salt (IV) to the free tetrazole (I) or to a hydrate or solvate thereof.